Hassett Michael J, Uno Hajime, Cronin Angel M, Carroll Nikki M, Hornbrook Mark C, Ritzwoller Debra P
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
Harvard Medical School, Boston, MA.
JNCI Cancer Spectr. 2018 Apr;2(2):pky024. doi: 10.1093/jncics/pky024. Epub 2018 Jun 28.
The treatments provided to and survival of patients with recurrent vs de novo stage IV advanced breast, lung, and colorectal cancer may differ but have not been well studied. Using population-based data from the Cancer Research Network for 4510 patients with advanced breast, lung, or colorectal cancer, we matched recurrent/de novo patients on demographic factors. We found longer survival for recurrent vs de novo lung cancer (182 matched pairs); no significant difference for colorectal cancer (332 matched pairs); and shorter survival for recurrent vs de novo breast cancer (219 matched pairs). Compared with recurrent cases, chemotherapy use and radiation therapy use were more common among de novo cases. Differences in treatment and survival between recurrent and de novo advanced cancer patients could inform prognostic estimates and clinical trial design.
复发性与原发性IV期晚期乳腺癌、肺癌和结直肠癌患者接受的治疗及生存率可能存在差异，但尚未得到充分研究。利用癌症研究网络的基于人群的数据，对4510例晚期乳腺癌、肺癌或结直肠癌患者进行分析，我们根据人口统计学因素对复发性/原发性患者进行了匹配。我们发现，复发性肺癌患者的生存期长于原发性肺癌患者（182对匹配病例）；结直肠癌患者无显著差异（332对匹配病例）；复发性乳腺癌患者的生存期短于原发性乳腺癌患者（219对匹配病例）。与复发性病例相比，原发性病例中化疗和放疗的使用更为常见。复发性和原发性晚期癌症患者在治疗和生存方面的差异可为预后评估和临床试验设计提供参考。
